Laidlaw Downgrades Mast Therapeutics (MSTX) to Neutral
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Laidlaw downgraded Mast Therapeutics (NYSE: MSTX) from Buy to Neutral.
Shares of Mast Therapeutics closed at $0.59 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades ARIAD Pharmaceuticals (ARIA) to Underweight
- Macquarie Downgrades CoBiz Financial (COBZ) to Neutral
- CLSA Downgrades Reynolds American (RAI) to Underperform
Create E-mail Alert Related CategoriesDowngrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!